A study that focused on children aged 5 to 12 years who lived in the United States found no difference between atropine 0.01% and placebo in treating myopia progression.
Atropine 0.01% was no more effective in slowing myopia progression compared with a placebo, according to a new study published in JAMA Ophthalmology. The study focused on children aged 5 to 12 years who lived in the United States.
In the United States, more than 44 million people are estimated to have myopia by 2050, with the prevalence also increasing worldwide. Atropine eye drops have been used to slow the progression of the disease, but most trials that evaluate their effectiveness take place outside of the United States. This study aimed to report the efficacy of atropine 0.01% compared with a placebo over 2 years.
The study was conducted from June 2018 to September 2022. Children were eligible if they had myopia of –1.00 diopter (D) to –6.00 D spherical equivalent refractive error (SER), astigmatism of 1.50 D or less in both eyes, and anisometropia of less than 1.00 D. Axial length, flat corneal radius, anterior chamber depth, and lens thickness were all measured. Participants were White (46%), Black (18%), Hispanic or Latino (16%), and East Asian (11%). The mean (SD) age was 10.1 (1.8) years, and 54% were female. Mean SER at baseline was –2.83 (1.10) D, and the mean axial length, 24.4 (0.8) mm.
All participants completed a 2- to 4-week phase to assess adherence to eye drops before being given the test drops. They were randomly assigned 2:1 to 1 eye drop of atropine 0.01% (n = 125) or placebo (n = 62). All participants were tasked with taking 1 dose nightly for 24 months followed by 6 months of follow-up after the eye-drops were stopped. No other treatments could be taken during this time. Follow-up visits took place at 6, 12, 18, 24, and 30 months following randomization. The primary outcome was assessing the change in cycloplegic SER from baseline to 24 months.
The mean SER was –2.83 (1.17) D in the atropine group and –2.83 (0.97) D in the placebo group at baseline. This changed to –3.64 (1.46) D in the atropine group and –3.54 (1.08) D in the placebo group after 24 months. The adjusted mean change in axial length from baseline to 24 months was 0.44 (95% CI, 0.39-0.50) mm in the atropine group and 0.45 (95% CI, 0.37-0.52) mm in the placebo group.
The researchers found a mean change in SER at 30 months after randomization of –0.94 (0.77) D in the atropine group and –0.88 (0.71) D in the placebo group. Corresponding mean changes in axial length were 0.51 (0.35) mm and 0.49 (0.32) mm.
Potential limitations on these findings include that there was no objective measure for eye drop use, and the family-reported usage may have overestimated adherence. In addition, the COVID-19 pandemic caused some virtual visits at 6, 12, and 18 months.
The researchers concluded that atropine 0.01% was not effective in slowing myopia progression in children aged 5 to 12 years with low to moderate myopia compared with placebo.
Reference
Repka MX, Weise KK, Chandler DL, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. Published online July 13, 2023. doi:10.1001/jamaophthalmol.2023.2855
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More